EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment

Christopher E. M. Griffiths, Antonio Costanzo, Kim A. Papp, David Rosmarin, Luis Puig, Andrew Blauvelt, Krista Wixted, José M. López Pinto, Jérémy Lambert, Rhys Warham, George Han

SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s895

DOI: 10.25251/6ngenr47 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Real-world psoriasis treatment may be interrupted. While bimekizumab has demonstrated durable responses through 2 years’ retreatment following interruption,[1] it is important to continue assessing how well responses are recaptured/maintained over longer periods upon retreatment. Here, we assess the ability of patients with moderate to severe psoriasis to recapture and maintain skin responses after withdrawal from bimekizumab and subsequent retreatment, and report the long-term durability of treatment responses over an extended follow-up period (up to 4 years) in patients who stopped and then restarted bimekizumab. Procedure: Data are reported from the BE READY phase 3 trial/BE BRIGHT open-label extension (OLE).[2,3] Patients were randomized to bimekizumab 320mg every 4 weeks (Q4W), achieved ≥90% improvement from baseline in Psoriasis Area and Severity Index (PASI90) at Week 16, then were rerandomized to placebo for a 40-week randomized-withdrawal period before OLE entry. Patients maintaining PASI75 continued placebo to Week 56, switching to bimekizumab Q4W in the OLE. Relapsing patients (

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →